期刊文献+

肾血管性高血压大鼠血清中血管性假血友病因子和高敏C反应蛋白动态变化 被引量:5

The Dynamic Changes of Serum Von Willebrand Factor and High Sensitivity C-Reactive Protein in Renovascular Hypertensive Rats
下载PDF
导出
摘要 目的研究易卒中型肾血管性高血压大鼠血清中血管性假血友病因子和高敏C反应蛋白在高血压病程中的动态变化,并探讨血管性假血友病因子和高敏C反应蛋白在高血压脑动脉粥样硬化及脑卒中发生、发展中的作用。方法双肾双夹法复制肾血管性高血压大鼠模型,酶联免疫吸附试验检测肾血管性高血压大鼠血清中血管性假血友病因子和高敏C反应蛋白的含量,并分别与对照组和假手术组比较。结果术后第4、8、12周末,高血压组血清血管性假血友病因子和高敏C反应蛋白含量均较对照组和假手术组显著升高,且随造模时间延长,不同阶段高血压组血清血管性假血友病因子和高敏C反应蛋白含量也随之升高。结论随着高血压病情进展,血清中血管性假血友病因子含量和高敏C反应蛋白含量也同步升高,两者均参与高血压动脉粥样硬化的发生、发展。高血压时血清中增高的血管性假血友病因子和高敏C反应蛋白均可能是其并发缺血性脑卒中的危险因素。 Aim To study dynamic changes of serum von Willebrand factor (vWF) and high sensitivity C-reactive protein (hs-CRP) in renovascular hypertensive rats, and to investigate the effect of vWF and hs-CRP in the deployment of atherosclerosis (As) andstmke. Methods vWFandhs-CRPwere measured with enzyme linked immunoabsorbent assay (ELISA), the results were compared with the control group and sham-opetated group. Results At the end of 4,8,12 weeks after the operation,the concenrations of serum vWF and hs-CRP were significantly increased compared with the control group and sham-operated group; the blood pressure were increasing in the hypertensive group after the operation, and the coneenrations of serum vWF and hs-CRP were increasing simultaneously. Conclusion When tire blood pressure were increasing, the concenrations of serum vWF and hs-CRP were increasing simultaneously; vWF and hs-CRP played vital roles in As. The high coneenrations of serum vWF and hs-CRP might be the risk factors to ischemic stroke.
出处 《中国动脉硬化杂志》 CAS CSCD 2007年第8期606-608,共3页 Chinese Journal of Arteriosclerosis
关键词 病理学与病理生理学 肾血管性高血压 血管性假血友病因子 高敏C反应蛋白 动脉粥样硬化 脑卒中 Renovascular Hypertension Von Willebrand Factor High Sensitivity C-Reactive Protein Atherosclerosis Stroke
  • 相关文献

参考文献11

  • 1Zeng JS, Zhang YQ, Mo JW, Su ZP, Huang RX. Two-kidney two clip renovascular hypertensive rars can be used as stroke-prone rars [J]. Stroke, 1998, 29:1 708-714.
  • 2王东,蒋湘莲,聂亚雄.高血压大鼠模型的研究进展[J].中国动脉硬化杂志,2006,14(3):271-273. 被引量:32
  • 3李志梅,潘殿卿,王红燕,朱建国.早期高血压患者血浆VWF、GMP-140、Fbg含量及t-PA、PAI-1活性变化及临床意义[J].脑与神经疾病杂志,2000,8(2):92-93. 被引量:1
  • 4水华,杨成悌,辛楠,余静.高血压病患者血管内皮损伤及凝血、纤溶指标变化的研究[J].高血压杂志,2002,10(4):314-316. 被引量:28
  • 5Collet JP, Montalescot G, Vicaut E, Ankri A, Walylo F, Lesty C, et al. Acute release of plasminogen activator inhibitor-1 in ST-segrment elevation myocardial infrarction predicts mortality [J]. Ciretdation, 2003, 10: 391-394.
  • 6Blann AD, Waite MA. Von Willebrand factor and soluble E-selecfn in hyper- tension: influence of treatment and value in predicting the progression of athero-aclevasis[J]. Coron Art Dis, 1996, 7 (2) : 143-147.
  • 7Roberts WL, Sedrick R, Moulton L, Spencer A, Rifai N. Evaluation of four automated high-senifivity C-reactive protein methods: implications for clinical and epidemiological applications [J]. Clin Chem, 2000, 46 (4) : 461-468.
  • 8张微微,周小英,黄勇华.不同类型脑梗死患者血清C-反应蛋白的检测及临床意义[J].中华检验医学杂志,2004,27(11):781-783. 被引量:35
  • 9Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis [J]. Circ ulation,2002, 1115 (9): 1 135-143.
  • 10Devaraj S,Xu DY,Jialal I.C-reactive protein increases plasminogen activator inhibitor-1 espression and activity in human aortic endothelial cells:implications for the metabolic syndrome and atherothrombosis[J].Circulation.2003,107(3):398-404.

二级参考文献39

共引文献92

同被引文献24

  • 1吴爱明,张冬梅,王硕仁,孙逸坤,牛福玲,吕晞滢,索红亮.高血压合并脑梗死患者血清基质金属蛋白酶-9水平的变化及其危险因素分析[J].临床神经病学杂志,2008,21(6):444-445. 被引量:5
  • 2张毅,蔡琰,苗玲.基质金属蛋白酶-9与缺血性脑损伤和脑梗死后出血的关系[J].临床神经病学杂志,2005,18(5):397-398. 被引量:11
  • 3张莉娜,陈健尔,张涛,崔军.高血压流行特征与相关因素调查[J].中国公共卫生,2006,22(1):93-94. 被引量:95
  • 4Jackson ZS, Gotlieb AI, Langille BL. Wall tissue remodeling regulates longitudenal tension in arteries[J]. Circ Res, 2002,90(8): 918-925.
  • 5Zeng JH, Zhang YQ, Mo JW, etal. Two-kidney, two cliprenovascular hypertensive rats can be used as stroke-prone rats[J].Stroke,1998,29(8):1708-1714.
  • 6Newby AC. Dual role of matrix metallop roteinases(Matrixins)in intimal thickening and atherosclerotic plaque rupture[J]. Physiol Rev, 2005,85(1) 1-31.
  • 7Tayehjee MH, Nadar S, Blann AD, etal. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the anglo-scandinavian cardiac outcomes trial (ASCOT) [J]. Am J Hypertens,2004,17(9) :764-769.
  • 8Bendeck MP. Matrix metalloproteinases: are they antiatherogenic hut proaneurysmal[J]. Circ Res,2002,90(8) :836-838.
  • 9Castellanos M, Sobrino T, Millan M, et al. Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenehymal hematoma after thrombolytie therapy in acuteischemic stroke:a multicenter confirmatory study [J]. Stroke,2007,38(6) : 1855-1859.
  • 10Mceniery CM, Wallace S, Dakham Z, et al. Matrix metalloproteinase 9(MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness[J]. Arterioscler Thromb Vasc Biol,2005,25(2)372-378.

引证文献5

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部